Autres langues Alector, Inc.

Actions

ALEC

US0144421072

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 24/04/2024			Varia. 5j.	Varia. 1 janv.
5,25 ^USD	-1,69 %		-1,13 %	-34,21 %

21/03	Alector, Inc. annonce des changements au sein de son conseil d'administration	CI
13/03	Transcript : Alector, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Certain Restricted Stock Units of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	17/04
Certain Options of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	17/04
Certain Common Stock of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	17/04
Alector, Inc. Announces Board Changes	21/03
Alector to Participate in Upcoming Healthcare Conferences	28/02
Alector: Q4 Earnings Snapshot	27/02
Alector, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Alector, Inc. Provides Revenue Guidance for the Year Ending 2024	27/02
Alector, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	27/02
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	27/02
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call	20/02
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease	08/02
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease	08/02
Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer?S Disease	08/02
Alector, GSK Say FDA Grants Breakthrough Therapy Label For Frontotemporal Dementia Treatment	07/02
GSK : statut de traitement novateur dans la démence	07/02
Alector, GSK Get FDA Breakthrough Designation for Latozinemab	07/02
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)	07/02
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)	07/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Alector, Inc.

Actions

ALEC

US0144421072

Autres langues

Filtres